In vitro methods in human drug biotransformation research: Implications for cancer chemotherapy

Toxicology in Vitro

Volumn 20, Issue 2, 2006, Pages 135-153

  Hariparsad, N ^a   Sane, R S ^a   Strom, S C ^b   Desai, P B ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Anticancer; Biotransformation; In vitro; Induction; Inhibition; Reaction phenotyping

Indexed keywords

ALITRETINOIN; ANTINEOPLASTIC AGENT; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOCETAXEL; DOXORUBICIN; ENZYME INHIBITOR; EPIRUBICIN; ETOPOSIDE; EXEMESTANE; FLUTAMIDE; GEFITINIB; IFOSFAMIDE; IMATINIB; IRINOTECAN; LETROZOLE; NAVELBINE; PACLITAXEL; PROCARBAZINE; RALOXIFENE; SEMAXANIB; TAMOXIFEN; TENIPOSIDE; THIOTEPA; TOREMIFENE; UNINDEXED DRUG; VINCRISTINE; VINDESINE;

ACCURACY; BIOTRANSFORMATION; CANCER CHEMOTHERAPY; CELL FRACTIONATION; CELL INTERACTION; CELL LINE; CRYOPRESERVATION; CYTOSOLIC FRACTION; DNA FINGERPRINTING; DRUG APPROVAL; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RESEARCH; DRUG USE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE COMPLEX; HUMAN; IC 50; IN VITRO STUDY; LIVER CELL CULTURE; LIVER MICROSOME; LIVER SLICE; METABOLIC INHIBITION; NONHUMAN; PHENOTYPE; SHORT SURVEY; TRANSGENIC ANIMAL;

ANIMALIA;

EID: 30644476703     PISSN: 08872333     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tiv.2005.06.049     Document Type: Review

References (167)

1. Anonymous, 2000. Exemestane for advanced breast cancer. The Medical Letter on Drugs and Therapeutics 42 (1076), 35-36.
2. T.E. Akiyama, and F.J. Gonzalez Regulation of P450 genes by liver-enriched transcription factors and nuclear receptors Biochimica et Biophysica Acta 1619 3 2003 223 234
3. J.H. Ansede, and D.R. Thakker High-throughput screening for stability and inhibitory activity of compounds toward cytochrome P450-mediated metabolism Journal of Pharmaceutical Sciences 93 2 2004 239 255
4. M. Anttila, R. Valavaara, S. Kivinen, and J. Maenpaa Pharmacokinetics of toremifene Journal of Steroid Biochemistry 36 3 1990 249 252
5. Z. Araya, and K. Wikvall 6alpha-hydroxylation of taurochenodeoxycholic acid and lithocholic acid by CYP3A4 in human liver microsomes Biochimica et Biophysica Acta 1438 1 1999 47 54
6. U. Baccarani, A. Sanna, A. Cariani, M. Sainz, G.L. Adani, D. Lorenzin, D. Montanaro, M. Scalamogna, G. Piccolo, A. Risaliti, F. Bresadola, and A. Donini Cryopreserved human hepatocytes from cell bank: in vitro function and clinical application Transplantation Proceedings 37 1 2005 256 259
7. J.L. Barwick, L.C. Quattrochi, A.S. Mills, C. Potenza, R.H. Tukey, and P.S. Guzelian Trans-species gene transfer for analysis of glucocorticoid- inducible transcriptional activation of transiently expressed human CYP3A4 and rabbit CYP3A6 in primary cultures of adult rat and rabbit hepatocytes Molecular Pharmacology 50 1 1996 10 16
8. M.K. Bayliss, J.A. Bell, W.N. Jenner, G.R. Park, and K. Wilson Utility of hepatocytes to model species differences in the metabolism of loxtidine and to predict pharmacokinetic parameters in rat, dog and man Xenobiotica; The Fate of Foreign Compounds in Biological Systems 29 3 1999 253 268
9. M.N. Berry, H.J. Halls, and M.B. Grivell Techniques for pharmacological and toxicological studies with isolated hepatocyte suspensions Life Sciences 51 1 1992 1 16
10. D.J. Bickett, P.I. MacKenzie, M.E. Veronese, and J.O. Miners In vitro approaches can predict human drug metabolism Trends in Pharmacological Sciences 14 8 1993 292 294
11. G.D. Block, J. Locker, W.C. Bowen, B.E. Petersen, S. Katyal, S.C. Strom, T. Riley, T.A. Howard, and G.K. Michalopoulos Population expansion, clonal growth, and specific differentiation patterns in primary cultures of hepatocytes induced by HGF/SF, EGF and TGF alpha in a chemically defined (HGM) medium The Journal of Cell Biology 132 6 1996 1133 1149
12. B. Blumberg, W. Sabbagh Jr., H. Juguilon, J. Bolado Jr., C.M. van Meter, E.S. Ong, and R.M. Evans SXR, a novel steroid and xenobiotic-sensing nuclear receptor Genes and Development 12 20 1998 3195 3205
13. D.J. Boocock, K. Brown, A.H. Gibbs, E. Sanchez, K.W. Turteltaub, and I.N. White Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA Carcinogenesis 23 11 2002 1897 1901
14. B. Burchell, and M.W. Coughtrie Genetic and environmental factors associated with variation of human xenobiotic glucuronidation and sulfation Environmental Health Perspectives 105 Suppl 1997 4739 4747
15. B. Burchell, C.H. Brierley, and D. Rance Specificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidation Life Sciences 57 20 1995 1819 1831
16. B. Burchell, M. Soars, G. Monaghan, A. Cassidy, D. Smith, and B. Ethell Drug-mediated toxicity caused by genetic deficiency of UDP- glucuronosyltransferases Toxicology Letters 112-113 2000 333 340
17. A.U. Buzdar, J.F. Robertson, W. Eiermann, and J.M. Nabholtz An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane Cancer 95 9 2002 2006 2016
18. C. Cavin, K. Mace, E.A. Offord, and B. Schilter Protective effects of coffee diterpenes against aflatoxin B1-induced genotoxicity: mechanisms in rat and human cells Food and Chemical Toxicology: An International Journal Published for the British Industrial Biological Research Association 39 6 2001 549 556
19. V. Cenacchi, S. Baratte, P. Cicioni, E. Frigerio, J. Long, and C. James LC-MS-MS determination of exemestane in human plasma with heated nebulizer interface following solid-phase extraction in the 96 well plate format Journal of Pharmaceutical and Biomedical Analysis 22 3 2000 451 460
20. Y. Chen, G. Kissling, M. Negishi, and J.A. Goldstein The nuclear receptors constitutive androstane receptor and pregnane X receptor cross-talk with hepatic nuclear factor 4alpha to synergistically activate the human CYP2C9 promoter Journal of Pharmacology and Experimental Therapeutics 314 3 2005 1125 1133
21. T.L. Chen, J.L. Passos-Coelho, D.A. Noe, M.J. Kennedy, K.C. Black, O.M. Colvin, and L.B. Grochow Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation Cancer Research 55 4 1995 810 816
22. R.J. Chenery, A. Ayrton, H.G. Oldham, P. Standring, S.J. Norman, T. Seddon, and R. Kirby Diazepam metabolism in cultured hepatocytes from rat, rabbit, dog, guinea pig, and man Drug Metabolism and Disposition: The Biological Fate of Chemicals 15 3 1987 312 317
23. G.M. Church, and W. Gilbert Genomic sequencing Proceedings of the National Academy of Sciences of the United States of America 81 7 1984 1991 1995
24. M. Ciotti, N. Basu, M. Brangi, and I.S. Owens Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus Biochemical and Biophysical Research Communications 260 1 1999 199 202
25. D.E. Colburn, F.J. Giles, D. Oladovich, and J.A. Smith In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin Hematology 9 3 2004 217 221
26. J.A. Coundouris, M.H. Grant, J. Engeset, J.C. Petrie, and G.M. Hawksworth Cryopreservation of human adult hepatocytes for use in drug metabolism and toxicity studies Xenobiotica; The Fate of Foreign Compounds in Biological Systems 23 12 1993 1399 1409
27. C.L. Crespi, R. Langenbach, and B.W. Penman Human cell lines, derived from AHH-1 TK+/- human lymphoblasts, genetically engineered for expression of cytochromes P450 Toxicology 82 1-3 1993 89 104
28. H.K. Crewe, S.W. Ellis, M.S. Lennard, and G.T. Tucker Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes Biochemical Pharmacology 53 2 1997 171 178
29. H.K. Crewe, L.M. Notley, R.M. Wunsch, M.S. Lennard, and E.M. Gillam Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4′-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen Drug Metabolism and Disposition: The Biological Fate of Chemicals 30 8 2002 869 874
30. K.M. Crommentuyn, J.H. Schellens, J.D. van den Berg, and J.H. Beijnen In-vitro metabolism of anti-cancer drugs, methods and applications: paclitaxel, docetaxel, tamoxifen and ifosfamide Cancer Treatment Reviews 24 5 1998 345 366
31. D.M. Cross, J.A. Bell, and K. Wilson Kinetics of ranitidine metabolism in dog and rat isolated hepatocytes Xenobiotica; The Fate of Foreign Compounds in Biological Systems 25 4 1995 367 375
32. R. Curi-Pedrosa, M. Daujat, L. Pichard, J.C. Ourlin, P. Clair, L. Gervot, P. Lesca, J. Domergue, H. Joyeux, and G. Fourtanier Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture The Journal of Pharmacology and Experimental Therapeutics 269 1 1994 384 392
33. P. Daniel, S.J. Gaskell, H. Bishop, C. Campbell, and R.I. Nicholson Determination of tamoxifen and biologically active metabolites in human breast tumours and plasma European Journal of Cancer and Clinical Oncology 17 11 1981 1183 1189
34. P. David, C. Viollon, E. Alexandre, A. Azimzadeh, L. Nicod, P. Wolf, D. Jaeck, K. Boudjema, and L. Richert Metabolic capacities in cultured human hepatocytes obtained by a new isolating procedure from non-wedge small liver biopsies Human and Experimental Toxicology 17 10 1998 544 553
35. K. De Smet, T. Bruning, M. Blaszkewicz, H.M. Bolt, A. Vercruysse, and V. Rogiers Biotransformation of trichloroethylene in collagen gel sandwich cultures of rat hepatocytes Archives of Toxicology 74 10 2000 587 592
36. Z. Desta, B.A. Ward, N.V. Soukhova, and D.A. Flockhart Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6 The Journal of Pharmacology and Experimental Therapeutics 310 3 2004 1062 1075
37. M.T. Donato, M.J. Gomez-Lechon, and J.V. Castell Effect of xenobiotics on monooxygenase activities in cultured human hepatocytes Biochemical Pharmacology 39 8 1990 1321 1326
38. K. Dorko, P.D. Freeswick, F. Bartoli, L. Cicalese, B.A. Bardsley, A. Tzakis, and A.K. Nussler A new technique for isolating and culturing human hepatocytes from whole or split livers not used for transplantation Cell Transplantation 3 5 1994 387 395
39. T. Ebner, and B. Burchell Substrate specificities of two stably expressed human liver UDP-glucuronosyltransferases of the UGT1 gene family Drug Metabolism and Disposition: The Biological Fate of Chemicals 21 1 1993 50 55
40. S. Ekins Past, present, and future applications of precision-cut liver slices for in vitro xenobiotic metabolism Drug Metabolism Reviews 28 4 1996 591 623
41. S. Ekins, B.J. Ring, J. Grace, D.J. McRobie-Belle, and S.A. Wrighton Present and future in vitro approaches for drug metabolism Journal of Pharmacological and Toxicological Methods 44 1 2000 313 324
42. J.L. Ferrero, and K. Brendel Liver slices as a model in drug metabolism Advances in Pharmacology 43 1997 131 169
43. M.B. Fisher, K. Campanale, B.L. Ackermann, M. VandenBranden, and S.A. Wrighton In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin Drug Metabolism and Disposition: The Biological Fate of Chemicals 28 5 2000 560 566
44. M. Garcia, J. Rager, Q. Wang, R. Strab, I.J. Hidalgo, A. Owen, and J. Li Cryopreserved human hepatocytes as alternative in vitro model for cytochrome p450 induction studies. In vitro cellular and developmental biology Animal 39 7 2003 283 287
45. J. George, B. Goodwin, C. Liddle, M. Tapner, and G.C. Farrell Time-dependent expression of cytochrome P450 genes in primary cultures of well-differentiated human hepatocytes The Journal of Laboratory and Clinical Medicine 129 6 1997 638 648
46. S. Gerbal-Chaloin, J.M. Pascussi, L. Pichard-Garcia, M. Daujat, F. Waechter, J.M. Fabre, N. Carrere, and P. Maurel Induction of CYP2C genes in human hepatocytes in primary culture Drug Metabolism and Disposition: The Biological Fate of Chemicals 29 3 2001 242 251
47. M.J. Gomez-Lechon, M.T. Donato, J.V. Castell, and R. Jover Human hepatocytes in primary culture: the choice to investigate drug metabolism in man Current Drug Metabolism 5 5 2004 443 462
48. B. Goodwin, E. Hodgson, and C. Liddle The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module Molecular Pharmacology 56 6 1999 1329 1339
49. L. Goria-Gatti, A. Iannone, A. Tomasi, G. Poli, and E. Albano In vitro and in vivo evidence for the formation of methyl radical from procarbazine: a spin-trapping study Carcinogenesis 13 5 1992 799 805
50. F.P. Guengerich, A. Parikh, E.F. Johnson, T.H. Richardson, C. von Wachenfeldt, J. Cosme, F. Jung, C.P. Strassburg, M.P. Manns, R.H. Tukey, M. Pritchard, S. Fournel-Gigleux, and B. Burchell Heterologous expression of human drug-metabolizing enzymes Drug Metabolism and Disposition: The Biological Fate of Chemicals 25 11 1997 1234 1241
51. B. Hagenauer, A. Salamon, T. Thalhammer, O. Kunert, E. Haslinger, P. Klingler, A.M. Senderowicz, E.A. Sausville, and W. Jager In vitro glucuronidation of the cyclin-dependent kinase inhibitor flavopiridol by rat and human liver microsomes: involvement of UDP-glucuronosyltransferases 1A1 and 1A9 Drug Metabolism and Disposition: The Biological Fate of Chemicals 29 4 Pt 1 2001 407 414
52. C. Handschin, and U.A. Meyer Induction of drug metabolism: the role of nuclear receptors Pharmacological Reviews 55 4 2003 649 673
53. N. Hanioka, S. Ozawa, H. Jinno, T. Tanaka-Kagawa, T. Nishimura, M. Ando, and J. Sawadi Ji Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytochrome P450 enzymes Drug Metabolism and Disposition 30 4 2002 391 396
54. D. Harding, S. Fournel-Gigleux, M.R. Jackson, and B. Burchell Cloning and substrate specificity of a human phenol UDP-glucuronosyltransferase expressed in COS-7 cells Proceedings of the National Academy of Sciences of the United States of America 85 22 1988 8381 8385
55. N. Hariparsad, S.C. Nallani, R.S. Sane, D.J. Buckley, A.R. Buckley, and P.B. Desai Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital Journal of Clinical Pharmacology 44 11 2004 1273 1281
56. J.W. Harris, A. Rahman, B.R. Kim, F.P. Guengerich, and J.M. Collins Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme Cancer Research 54 15 1994 4026 4035
57. R.B. Howard, A.K. Christensen, F.A. Gibbs, and L.A. Pesch The enzymatic preparation of isolated intact parenchymal cells from rat liver The Journal of Cell Biology 35 3 1967 675 684
58. M. Hu, Y. Li, C.M. Davitt, S.M. Huang, K. Thummel, B.W. Penman, and C.L. Crespi Transport and metabolic characterization of Caco-2 cells expressing CYP3A4 and CYP3A4 plus oxidoreductase Pharmaceutical Research 16 9 1999 1352 1359
59. A.D. Huitema, T. Kerbusch, M.M. Tibben, S. Rodenhuis, and J.H. Beijnen Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens Cancer Chemotherapy and Pharmacology 46 2 2000 119 127
60. J.N. Ingle, V.J. Suman, P.A. Johnson, J.E. Krook, J.A. Mailliard, R.H. Wheeler, C.L. Loprinzi, E.A. Perez, V.C. Jordan, and M. Dowsett Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 5 7 1999 1642 1649
61. F. Innocenti, and M.J. Ratain Update on pharmacogenetics in cancer chemotherapy European Journal of Cancer 38 5 2002 639 644
62. F. Innocenti, L. Iyer, J. Ramirez, M.D. Green, and M.J. Ratain Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7 Drug Metabolism and Disposition: The Biological Fate of Chemicals 29 5 2001 686 692
63. M. Ito, K. Yamamoto, Y. Maruo, H. Sato, Y. Fujiyama, and T. Bamba Effect of a conserved mutation in uridine diphosphate glucuronosyltransferase 1A1 and 1A6 on glucuronidation of a metabolite of flutamide European Journal of Clinical Pharmacology 58 1 2002 11 14
64. L. Iyer, C.D. King, P.F. Whitington, M.D. Green, S.K. Roy, T.R. Tephly, B.L. Coffman, and M.J. Ratain Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes The Journal of Clinical Investigation 101 4 1998 847 854
65. P.A. Jacobson, K. Green, A. Birnbaum, and R.P. Remmel Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA Cancer Chemotherapy and Pharmacology 49 6 2002 461 467
66. F. Jacolot, I. Simon, Y. Dreano, P. Beaune, C. Riche, and F. Berthou Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes Biochemical Pharmacology 41 12 1991 1911 1919
67. H.O. Jauregui, S. Naik, H. Santangini, J. Pan, D. Trenkler, and C. Mullon Primary cultures of rat hepatocytes in hollow fiber chambers. In vitro cellular and developmental biology Animal 30 1 1994 23 29
68. Y. Jin, Z. Desta, V. Stearns, B. Ward, H. Ho, K.H. Lee, T. Skaar, A.M. Storniolo, L. Li, A. Araba, R. Blanchard, A. Nguyen, L. Ullmer, J. Hayden, S. Lemler, R.M. Weinshilboum, J.M. Rae, D.F. Hayes, and D.A. Flockhart CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment Journal of the National Cancer Institute 97 1 2005 30 39
69. D.R. Jones, and S.D. Hall Mechanism-based inhibition of human cytochrome P450: in vitro kinetics and in vitro-in vivo correlations (Chapter 10) A.D. Rodrigues Drug-Drug Interactions 2002 Marcel Dekker, Inc New York 387 438
70. Y. Jounaidi Cytochrome P450-based gene therapy for cancer treatment: from concept to the clinic Current Drug Metabolism 3 6 2002 609 622
71. J. Kajita, T. Kuwabara, H. Kobayashi, and S. Kobayashi CYP3A4 is mainly responsibile for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes Drug Metabolism and Disposition: The Biological Fate of Chemicals 28 9 2000 1121 1127
72. T. Kaku, K. Ogura, T. Nishiyama, T. Ohnuma, K. Muro, and A. Hiratsuka Quaternary ammonium-linked glucuronidation of tamoxifen by human liver microsomes and UDP-glucuronosyltransferase 1A4 Biochemical Pharmacology 67 11 2004 2093 2102
73. T. Kaku, K. Ogura, T. Nishiyama, T. Ohnuma, K. Muro, and A. Hiratsuka Quaternary ammonium-linked glucuronidation of tamoxifen by human liver microsomes and UDP-glucuronosyltransferase 1A4 Biochemical Pharmacology 67 11 2004 2093 2102
74. S.J. Karpen Nuclear receptor regulation of hepatic function Journal of Hepatology 36 6 2002 832 850
75. N. Kasai, T. Sakaki, R. Shinkyo, S. Ikushiro, T. Iyanagi, M. Ohta, and K. Inouye Metabolism of 26,26,26,27,27,27-F6-1 alpha,23S,25-trihydroxyvitamin D3 by human UDP-glucuronosyltransferase 1A3 Drug Metabolism and Disposition: The Biological Fate of Chemicals 33 1 2005 102 107
76. I. Kawahara, Y. Kato, H. Suzuki, M. Achira, K. Ito, C.L. Crespi, and Y. Sugiyama Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1,1-dimethylethylaminocarbonyl) -4-[(furo[2, 3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)- phenylmethy lpentanamide and P-glycoprotein by valspodar in gene transfectant systems Drug Metabolism and Disposition: The Biological Fate of Chemicals 28 10 2000 1238 1243
77. T. Kawashiro, K. Yamashita, X.J. Zhao, E. Koyama, M. Tani, K. Chiba, and T. Ishizaki A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes The Journal of Pharmacology and Experimental Therapeutics 286 3 1998 1294 1300
78. D.C. Kemp, P.W. Fan, and J.C. Stevens Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance Drug Metabolism and Disposition: The Biological Fate of Chemicals 30 6 2002 694 700
79. E.D. Kharasch, M. Russell, K. Garton, G. Lentz, T.A. Bowdle, and K. Cox Assessment of cytochrome P450 3A4 activity during the menstrual cycle using alfentanil as a noninvasive probe Anesthesiology 87 1 1997 26 35
80. E.D. Kharasch, M. Russell, D. Mautz, K.E. Thummel, K.L. Kunze, A. Bowdle, and K. Cox The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions Anesthesiology 87 1 1997 36 50
81. E.D. Kharasch, C. Hoffer, A. Walker, and P. Sheffels Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity Clinical Pharmacology and Therapeutics 73 3 2003 199 208
82. E.D. Kharasch, K.E. Thummel, and P.B. Watkins CYP3A probes can quantitatively predict the in vivo kinetics of other CYP3A substrates and can accurately assess CYP3A induction and inhibition Molecular Interventions 5 3 2005 151 153
83. K.T. Kivisto, H.K. Kroemer, and M. Eichelbaum The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions British Journal of Clinical Pharmacology 40 6 1995 523 530
84. T.M. Klees, P. Sheffels, O. Dale, and E.D. Kharasch Metabolism of alfentanil by cytochrome p4503a (cyp3a) enzymes Drug Metabolism and Disposition: The Biological Fate of Chemicals 33 3 2005 303 311
85. S.A. Kliewer, J.M. Lehmann, and T.M. Willson Orphan nuclear receptors: shifting endocrinology into reverse Science 284 5415 1999 757 760
86. T.A. Kocarek, E.G. Schuetz, S.C. Strom, R.A. Fisher, and P.S. Guzelian Comparative analysis of cytochrome P4503A induction in primary cultures of rat, rabbit, and human hepatocytes Drug Metabolism and Disposition: The Biological Fate of Chemicals 23 3 1995 415 421
87. H.G. Koebe, C.J. Deglmann, R. Metzger, S. Hoerrlein, and F.W. Schildberg In vitro toxicology in hepatocyte bioreactors-extracellular acidification rate (EAR) in a target cell line indicates hepato-activated transformation of substrates Toxicology 154 1-3 2000 31 44
88. B.J. Komoroski, S. Zhang, H. Cai, J.M. Hutzler, R. Frye, T.S. Tracy, S.C. Strom, T. Lehmann, C.Y. Ang, Y.Y. Cui, and R. Venkataramanan Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures Drug Metabolism and Disposition: The Biological Fate of Chemicals 32 5 2004 512 518
89. V.E. Kostrubsky, L.D. Lewis, S.C. Strom, S.G. Wood, E.G. Schuetz, J.D. Schuetz, P.R. Sinclair, S.A. Wrighton, and J.F. Sinclair Induction of cytochrome P4503A by taxol in primary cultures of human hepatocytes Archives of Biochemistry and Biophysics 355 2 1998 131 136
90. V.E. Kostrubsky, V. Ramachandran, R. Venkataramanan, K. Dorko, J.E. Esplen, S. Zhang, J.F. Sinclair, S.A. Wrighton, and S.C. Strom The use of human hepatocyte cultures to study the induction of cytochrome P-450 Drug Metabolism and Disposition: The Biological Fate of Chemicals 27 8 1999 887 894
91. C.L. Krumdieck, J.E. dos Santos, and K.J. Ho A new instrument for the rapid preparation of tissue slices Analytical Biochemistry 104 1 1980 118 123
92. G.N. Kumar, and S. Surapaneni Role of drug metabolism in drug discovery and development Medicinal Research Reviews 21 5 2001 397 411
93. T.O. Lankisch, A. Vogel, S. Eilermann, A. Fiebeler, B. Krone, A. Barut, M.P. Manns, and C.P. Strassburg Identification and characterization of a functional TATA box polymorphism of the UDP glucuronosyltransferase 1A7 gene Molecular Pharmacology 67 5 2005 1732 1739
94. J.F. Le Bigot, J.M. Begue, J.R. Kiechel, and A. Guillouzo Species differences in metabolism of ketotifen in rat, rabbit and man: demonstration of similar pathways in vivo and in cultured hepatocytes Life Sciences 40 9 1987 883 890
95. C. Le Guellec, B. Lacarelle, P.H. Villard, H. Point, J. Catalin, and A. Durand Glucuronidation of propofol in microsomal fractions from various tissues and species including humans: effect of different drugs Anesthesia and Analgesia 81 4 1995 855 861
96. J.M. Lehmann, D.D. McKee, M.A. Watson, T.M. Willson, J.T. Moore, and S.A. Kliewer The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions The Journal of Clinical Investigation 102 5 1998 1016 1023
97. Levy, R.H., Thummel, K.E., Trager, W.F., 2000. Metabolic drug interactions. In: Anonymous (Ed.), 793. Lippincott, Williams, and Wilkins, Philadelphia.
98. C.W. Lewis, J.E. Smith, J.G. Anderson, and R.I. Freshney Increased cytotoxicity of food-borne mycotoxins toward human cell lines in vitro via enhanced cytochrome p450 expression using the MTT bioassay Mycopathologia 148 2 1999 97 102
99. A.P. Li, A. Rasmussen, L. Xu, and D.L. Kaminski Rifampicin induction of lidocaine metabolism in cultured human hepatocytes The Journal of Pharmacology and Experimental Therapeutics 274 2 1995 673 677
100. A.P. Li, M.K. Reith, A. Rasmussen, J.C. Gorski, S.D. Hall, L. Xu, D.L. Kaminski, and L.K. Cheng Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin Chemico-Biological Interactions 107 1-2 1997 17 30
101. A.P. Li, C. Lu, J.A. Brent, C. Pham, A. Fackett, C.E. Ruegg, and P.M. Silber Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential Chemico-Biological Interactions 121 1 1999 17 35
102. J.H. Lin, M. Chiba, I.W. Chen, K.J. Vastag, J.A. Nishime, B.D. Dorsey, S.R. Michelson, and S.L. McDaniel Time- and dose-dependent pharmacokinetics of L-754,394, an HIV protease inhibitor, in rats, dogs and monkeys The Journal of Pharmacology and Experimental Therapeutics 274 1 1995 264 269
103. J.H. Lin, I.W. Chen, M. Chiba, J.A. Nishime, and F.A. Deluna Route-dependent nonlinear pharmacokinetics of a novel HIV protease inhibitor: involvement of enzyme inactivation Drug Metabolism and Disposition: The Biological Fate of Chemicals 28 4 2000 460 466
104. P.I. Mackenzie, I.S. Owens, B. Burchell, K.W. Bock, A. Bairoch, A. Belanger, S. Fournel-Gigleux, M. Green, D.W. Hum, T. Iyanagi, D. Lancet, P. Louisot, J. Magdalou, J.R. Chowdhury, J.K. Ritter, H. Schachter, T.R. Tephly, K.F. Tipton, and D.W. Nebert The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence Pharmacogenetics 7 4 1997 255 269
105. D.J. Mangelsdorf, and R.M. Evans The RXR heterodimers and orphan receptors Cell 83 6 1995 841 850
106. D.J. Mangelsdorf, E.S. Ong, J.A. Dyck, and R.M. Evans Nuclear receptor that identifies a novel retinoic acid response pathway Nature 345 6272 1990 224 229
107. D.J. Mangelsdorf, C. Thummel, M. Beato, P. Herrlich, G. Schutz, K. Umesono, B. Blumberg, P. Kastner, M. Mark, and P. Chambon The nuclear receptor superfamily: the second decade Cell 83 6 1995 835 839
108. J. Marill, C.C. Capron, N. Idres, and G.G. Chabot Human cytochrome P450s involved in the metabolism of 9-cis- and 13-cis-retinoic acids Biochemical Pharmacology 63 5 2002 933 943
109. H. Martin, J.P. Sarsat, I. de Waziers, C. Housset, P. Balladur, P. Beaune, V. Albaladejo, and C. Lerche-Langrand Induction of cytochrome P450 2B6 and 3A4 expression by phenobarbital and cyclophosphamide in cultured human liver slices Pharmaceutical Research 20 4 2003 557 568
110. C.M. Masimirembwa, U. Bredberg, and T.B. Andersson Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges Clinical Pharmacokinetics 42 6 2003 515 528
111. R.H. Mathijssen, J. Verweij, P. de Bruijn, W.J. Loos, and A. Sparreboom Effects of St. John's wort on irinotecan metabolism Journal of the National Cancer Institute 94 16 2002 1247 1249
112. D. McKillop, A.D. McCormick, G.S. Miles, P.J. Phillips, K.J. Pickup, N. Bushby, and M. Hutchison In vitro metabolism of gefitinib in human liver microsomes Xenobiotica; The Fate of Foreign Compounds in Biological Systems 34 11-12 2004 983 1000
113. D. McKillop, A.D. McCormick, A. Millar, G.S. Miles, P.J. Phillips, and M. Hutchison Cytochrome P450-dependent metabolism of gefitinib Xenobiotica; The Fate of Foreign Compounds in Biological Systems 35 1 2005 39 50
114. B.A. Mico, D.A. Federowicz, M.G. Ripple, and W. Kerns In vivo inhibition of oxidative drug metabolism by, and acute toxicity of, 1-aminobenzotriazole (ABT). A tool for biochemical toxicology Biochemical Pharmacology 37 13 1988 2515 2519
115. N. Milosevic, H. Schawalder, and P. Maier Kupffer cell-mediated differential down-regulation of cytochrome P450 metabolism in rat hepatocytes European Journal of Pharmacology 368 1 1999 75 87
116. F. Nakazawa, H. Cai, K. Dorko, A. Abdelmeguid, T. Miki, J. Walldorf, T. Lehmann, and S.C. Strom Human hepatocyte isolation from cadaver donors Anonymous Proceedings of Falk Symposium-126 Hepatocyte Transplantation 2002 Kluwer Academic Publishers Lancaster, UK
117. S.C. Nallani, B. Goodwin, J.M. Maglich, D.J. Buckley, A.R. Buckley, and P.B. Desai Induction of cytochrome P450 3A by paclitaxel in mice: pivotal role of the nuclear xenobiotic receptor, pregnane X receptor Drug Metabolism and Disposition: The Biological Fate of Chemicals 31 5 2003 681 684
118. S.C. Nallani, B. Goodwin, A.R. Buckley, D.J. Buckley, and P.B. Desai Differences in the induction of cytochrome P450 3A4 by taxane anticancer drugs, docetaxel and paclitaxel, assessed employing primary human hepatocytes Cancer Chemotherapy and Pharmacology 54 3 2004 219 229
119. T. Nishiyama, K. Ogura, H. Nakano, T. Ohnuma, T. Kaku, A. Hiratsuka, K. Muro, and T. Watabe Reverse geometrical selectivity in glucuronidation and sulfation of cis- and trans-4-hydroxytamoxifens by human liver UDP-glucuronosyltransferases and sulfotransferases Biochemical Pharmacology 63 10 2002 1817 1830
120. T. Oguri, T. Takahashi, M. Miyazaki, T. Isobe, N. Kohno, P.I. Mackenzie, and Y. Fujiwara UGT1A10 is responsible for SN-38 glucuronidation and its expression in human lung cancers Anticancer Research 24 5A 2004 2893 2896
121. A. Ostrowska, D.C. Bode, J. Pruss, B. Bilir, G.D. Smith, and S. Zeisloft Investigation of functional and morphological integrity of freshly isolated and cryopreserved human hepatocytes Cell Tissue Bank 1 1 2000 55 68
122. L. Paoluzzi, A.S. Singh, D.K. Price, R. Danesi, R.H. Mathijssen, J. Verweij, W.D. Figg, and A. Sparreboom Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38 Journal of Clinical Pharmacology 44 8 2004 854 860
123. A. Parkinson An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials Toxicologic Pathology 24 1 1996 48 57
124. J.M. Pascussi, S. Gerbal-Chaloin, L. Drocourt, P. Maurel, and M.J. Vilarem The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors Biochimica et Biophysica Acta 1619 3 2003 243 253
125. K.C. Patki, L.L. von Moltke, J.S. Harmatz, L.M. Hesse, M.H. Court, and D.J. Greenblatt Effect of age on in vitro triazolam biotransformation in male human liver microsomes The Journal of Pharmacology and Experimental Therapeutics 308 3 2004 874 879
126. O. Pelkonen, E.H. Kaltiala, T.K. Larmi, and N.T. Karki Cytochrome P-450-linked monooxygenase system and drug-induced spectral interactions in human liver microsomes Chemico-Biological Interactions 9 3 1974 205 216
127. S. Phimmasone, and E.D. Kharasch A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans Clinical Pharmacology and Therapeutics 70 6 2001 505 517
128. T. Pillot, M. Ouzzine, S. Fournel-Gigleux, C. Lafaurie, A. Radominska, B. Burchell, G. Siest, and J. Magdalou Glucuronidation of hyodeoxycholic acid in human liver. Evidence for a selective role of UDP-glucuronosyltransferase 2B4 Journal of Biological Chemistry 268 34 1993 25636 25642
129. S.M. Pond, and T.N. Tozer First-pass elimination. Basic concepts and clinical consequences Clinical Pharmacokinetics 9 1 1984 1 25
130. A. Rahman, K.R. Korzekwa, J. Grogan, F.J. Gonzalez, and J.W. Harris Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8 Cancer Research 54 21 1994 5543 5546
131. V. Ramachandran, V.E. Kostrubsky, B.J. Komoroski, S. Zhang, K. Dorko, J.E. Esplen, S.C. Strom, and R. Venkataramanan Troglitazone increases cytochrome P-450 3A protein and activity in primary cultures of human hepatocytes Drug Metabolism and Disposition: The Biological Fate of Chemicals 27 10 1999 1194 1199
132. J. Ramirez, L. Iyer, K. Journault, P. Belanger, F. Innocenti, M.J. Ratain, and C. Guillemette In vitro characterization of hepatic flavopiridol metabolism using human liver microsomes and recombinant UGT enzymes Pharmaceutical Research 19 5 2002 588 594
133. J.L. Raucy, L. Mueller, K. Duan, S.W. Allen, S. Strom, and J.M. Lasker Expression and induction of CYP2C P450 enzymes in primary cultures of human hepatocytes The Journal of Pharmacology and Experimental Therapeutics 302 2 2002 475 482
134. J.M. Reid, M.J. Kuffel, J.K. Miller, R. Rios, and M.M. Ames Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1 Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 5 8 1999 2192 2197
135. B. Reinach, G. de Sousa, P. Dostert, R. Ings, J. Gugenheim, and R. Rahmani Comparative effects of rifabutin and rifampicin on cytochromes P450 and UDP-glucuronosyl-transferases expression in fresh and cryopreserved human hepatocytes Chemico-Biological Interactions 121 1 1999 37 48
136. V. Ribrag, L. Massaad, F. Janot, M.C. Bissery, O. Parise Jr., A. Gouyette, and G.G. Chabot Principal drug-metabolizing enzyme systems in L1210 leukemia sensitive or resistant to BCNU in vivo Leukemia Research 18 11 1994 829 835
137. J.K. Ritter, F. Chen, Y.Y. Sheen, R.A. Lubet, and I.S. Owens Two human liver cDNAs encode UDP-glucuronosyltransferases with 2 log differences in activity toward parallel substrates including hyodeoxycholic acid and certain estrogen derivatives Biochemistry (John Wiley & Sons) 31 13 1992 3409 3414
138. B. Rochat Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism Clinical Pharmacokinetics 44 4 2005 349 366
139. A.D. Rodrigues, and J.H. Lin Screening of drug candidates for their drug-drug interaction potential Current Opinion in Chemical Biology 5 4 2001 396 401
140. A. Rousseau, P. Marquet, J. Debord, C. Sabot, and G. Lachatre Adaptive control methods for the dose individualisation of anticancer agents Clinical Pharmacokinetics 38 4 2000 315 353
141. I. Royer, B. Monsarrat, M. Sonnier, M. Wright, and T. Cresteil Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs Cancer Research 56 1 1996 58 65
142. D. Roymans, P. Annaert, J. Van Houdt, A. Weygers, J. Noukens, C. Sensenhauser, J. Silva, C. Van Looveren, J. Hendrickx, G. Mannens, and W. Meuldermans Expression and induction potential of cytochromes P450 in human cryopreserved hepatocytes Drug Metabolism and Disposition: The Biological Fate of Chemicals 33 7 2005 1004 1016
143. D. Runge, C. Kohler, V.E. Kostrubsky, D. Jager, T. Lehmann, D.M. Runge, U. May, D.B. Stolz, S.C. Strom, W.E. Fleig, and G.K. Michalopoulos Induction of cytochrome P450 (CYP)1A1, CYP1A2, and CYP3A4 but not of CYP2C9, CYP2C19, multidrug resistance (MDR-1) and multidrug resistance associated protein (MRP-1) by prototypical inducers in human hepatocytes Biochemical and Biophysical Research Communications 273 1 2000 333 341
144. V.M. Samokyszyn, W.E. Gall, G. Zawada, M.A. Freyaldenhoven, G. Chen, P.I. Mackenzie, T.R. Tephly, and A. Radominska-Pandya 4-hydroxyretinoic acid, a novel substrate for human liver microsomal UDP-glucuronosyltransferase(s) and recombinant UGT2B7 Journal of Biological Chemistry 275 10 2000 6908 6914
145. A. Santos, S. Zanetta, T. Cresteil, A. Deroussent, F. Pein, E. Raymond, L. Vernillet, M.L. Risse, V. Boige, A. Gouyette, and G. Vassal Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 6 5 2000 2012 2020
146. E.G. Schuetz, J.D. Schuetz, S.C. Strom, M.T. Thompson, R.A. Fisher, D.T. Molowa, D. Li, and P.S. Guzelian Regulation of human liver cytochromes P-450 in family 3A in primary and continuous culture of human hepatocytes Hepatology (Baltimore, MD) 18 5 1993 1254 1262
147. M.B. Sewer, and E.T. Morgan Nitric oxide-independent suppression of P450 2C11 expression by interleukin-1beta and endotoxin in primary rat hepatocytes Biochemical Pharmacology 54 6 1997 729 737
148. J.M. Silva, S.H. Day, and D.A. Nicoll-Griffith Induction of cytochrome-P450 in cryopreserved rat and human hepatocytes Chemico-Biological Interactions 121 1 1999 49 63
149. M.G. Soars, B.J. Ring, and S.A. Wrighton The effect of incubation conditions on the enzyme kinetics of udp-glucuronosyltransferases Drug Metabolism and Disposition: The Biological Fate of Chemicals 31 6 2003 762 767
150. J.H. Son, K.H. Kim, Y.K. Nam, J.K. Park, and S.K. Kim Optimization of cryoprotectants for cryopreservation of rat hepatocyte Biotechnology Letters 26 10 2004 829 833
151. S.C. Strom, L.A. Pisarov, K. Dorko, M.T. Thompson, J.D. Schuetz, and E.G. Schuetz Use of human hepatocytes to study P450 gene induction Methods in Enzymology 272 1996 388 401
152. L. Sutherland, S. bin Senafi, T. Ebner, D.J. Clarke, and B. Burchell Characterisation of a human bilirubin UDP-glucuronosyltransferase stably expressed in hamster lung fibroblast cell cultures FEBS Letters 308 2 1992 161 164
153. P. Taavitsainen, M. Anttila, L. Nyman, H. Karnani, J.S. Salonen, and O. Pelkonen Selegiline metabolism and cytochrome P450 enzymes: in vitro study in human liver microsomes Pharmacology and Toxicology 86 5 2000 215 221
154. G.T. Tucker, J.B. Houston, and S.M. Huang Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a cosensus Pharmaceutical Research 18 8 2001 1071 1080
155. R.H. van Schaik Implications of cytochrome P450 genetic polymorphisms on the toxicity of antitumor agents Therapeutic Drug Monitoring 26 2 2004 236 240
156. Y. Watanabe, M. Nakajima, N. Ohashi, T. Kume, and T. Yokoi Glucuronidation of etoposide in human liver microsomes is specifically catalyzed by UDP-glucuronosyltransferase 1A1 Drug Metabolism and Disposition: The Biological Fate of Chemicals 31 5 2003 589 595
157. D.J. Waxman, A. Ko, and C. Walsh Regioselectivity and stereoselectivity of androgen hydroxylations catalyzed by cytochrome P-450 isozymes purified from phenobarbital-induced rat liver Journal of Biological Chemistry 258 19 1983 11937 11947
158. P. Wei, J. Zhang, D.H. Dowhan, Y. Han, and D.D. Moore Specific and overlapping functions of the nuclear hormone receptors CAR and PXR in xenobiotic response Pharmacogenomics Journal 2 2 2002 117 126
159. I.N. White, F. De Matteis, A.H. Gibbs, C.K. Lim, C.R. Wolf, C. Henderson, and L.L. Smith Species differences in the covalent binding of [14C]tamoxifen to liver microsomes and the forms of cytochrome P450 involved Biochemical Pharmacology 49 8 1995 1035 1042
160. R. Wooster, T. Ebner, L. Sutherland, D. Clarke, and B. Burchell Drug and xenobiotic glucuronidation catalysed by cloned human liver UDP- Glucuronosyltransferases stably expressed in tissue culture cell lines Toxicology 82 1-3 1993 119 129
161. P.D. Worboys, A. Bradbury, and J.B. Houston Kinetics of drug metabolism in rat liver slices. II. Comparison of clearance by liver slices and freshly isolated hepatocytes Drug Metabolism and Disposition: The Biological Fate of Chemicals 24 6 1996 676 681
162. P.D. Worboys, A. Bradbury, and J.B. Houston Kinetics of drug metabolism in rat liver slices. III. Relationship between metabolic clearance and slice uptake rate Drug Metabolism and Disposition: The Biological Fate of Chemicals 25 4 1997 460 467
163. Wrighton, S.A., Thummel, K.E., 2000. CYP3A. In: LevyThummel, R.H., Trager, K.E., Hansten, W.F., P.D., Eichelbaum, M. (Eds.), Metabolic Drug Interactions, vol. 115. Lippincott Williams and Wilkins, Philadelphia.
164. S. Yamagata, S. Ohmori, N. Suzuki, M. Yoshino, M. Hino, I. Ishii, and M. Kitada Metabolism of dacarbazine by rat liver microsomes contribution of CYP1A enzymes to dacarbazine N-demethylation Drug Metabolism and Disposition: The Biological Fate of Chemicals 26 4 1998 379 382
165. K. Zhang, P. Mack, and K.P. Wong Glutathione-related mechanisms in cellular resistance to anticancer drugs International Journal of Oncology 12 4 1998 871 882
166. X.J. Zhao, D.R. Jones, Y.H. Wang, S.W. Grimm, and S.D. Hall Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites Xenobiotica 32 10 2002 863 878
167. S. Zhou, S. Yung Chan, B. Cher Goh, E. Chan, W. Duan, M. Huang, and H.L. McLeod Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs Clinical Pharmacokinetics 44 3 2005 279 304